Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.54 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17583885 | 0.88 | ESR2 (0.58) | ESR2NR1H2ABHD6MAPTKDM4E | |
| SCHEMBL20216030 | 0.88 | ESR2 (0.55) | ESR2NR1H2ABHD6MAPTKDM4E | |
| SCHEMBL16039921 | 0.88 | ESR2 (0.58) | ESR2NR1H2ABHD6MAPTKDM4E | |
| SCHEMBL3603315 | 0.86 | NR1H2 (0.59) | ESR2NR1H2ABHD6MAPTKDM4E | |
| SCHEMBL15502974 | 0.85 | ESR2 (0.53) | ESR2NR1H2ABHD6MAPTKDM4E | |
| SCHEMBL17583937 | 0.85 | ACACB (0.54) | ESR2NR1H2MAPK1P2RX3ACACB | |
| SCHEMBL16039389 | 0.85 | AGTR2 (0.52) | ESR2NR1H2MAPK1ACACB | |
| SCHEMBL15502975 | 0.84 | ESR2 (0.52) | ESR2NR1H2ABHD6MAPTKDM4E | |
| SCHEMBL15502973 | 0.84 | ESR2 (0.52) | ESR2NR1H2ABHD6MAPTKDM4E | |
| SCHEMBL3600122 | 0.84 | ESR2 (0.52) | ESR2NR1H2ABHD6MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9713615-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9713615-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9713615-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | Ocuphire Pharma, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | Ocuphire Pharma, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | Ocuphire Pharma, Inc. | 2016-05-19 | — | — | US | disclosed |
| EP-2970203-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS | Rexahn Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9193707-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193707-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193707-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| WO-2014143960-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014143960-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275129-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275129-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275129-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275129-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | HRAS, RECQL, CDK4 | ESR2 3026/4885NR1H2 433/4885ABHD6 4376/4885 |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | HRAS, RECQL, CDK4 | ESR2 3026/4885NR1H2 433/4885ABHD6 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.